```html

Anthrax – Complete Medical Guide

Overview

Anthrax is a serious infectious disease caused by the bacterium Bacillus anthracis. The organism forms hardy spores that can survive in soil for decades. When these spores enter the body—through the skin, inhalation, or ingestion—they germinate into active bacteria that produce toxins, leading to illness.

Historically, anthrax has been an occupational disease of people who work with livestock, wool, hides, or animal products. In recent decades, it has also gained attention as a potential bioterrorism agent because aerosolised spores are highly lethal.

• Global prevalence: Sporadic cases occur worldwide, especially in agricultural regions of Africa, Asia, and the Middle East. The World Health Organization (WHO) reports fewer than 20,000 human cases per year, the majority being cutaneous.
• U.S. data: According to the CDC, from 2000‑2022 there were only 31 confirmed anthrax cases in the United States, most linked to occupational exposure.
• Who it affects: Farmers, veterinarians, laboratory workers, and people handling animal products are at highest risk. Travelers to endemic areas who consume undercooked meat are also vulnerable.

Symptoms

Anthrax presents in three classic forms—cutaneous, inhalational, and gastrointestinal—each with a distinct symptom pattern. A fourth, injectional anthrax, has been reported in heroin users.

Cutaneous Anthrax

• Initial painless papule at the site of spore entry (often on arms, neck, or face).
• Within 1–2 days, the papule becomes a vesicle that ruptures, forming a painless ulcer with a characteristic black “eschar” (eschar = dead tissue).
• Surrounding edema (swelling) and erythema (redness) that can spread 2–3 cm beyond the lesion.
• Fever, chills, and malaise in 10–20 % of cases.

Inhalational (Pulmonary) Anthrax

• Incubation 1–7 days after exposure.
• Early flu‑like symptoms: fever, dry cough, sore throat, malaise, myalgia.
• Rapid progression to severe dyspnea, chest pain, and broad‑based wheezing.
• Hypotension, shock, and potentially hemorrhagic mediastinitis (bleeding into the space around the heart).
• High mortality (>80 % without early antibiotics).

Gastrointestinal Anthrax

• Usually follows ingestion of contaminated meat.
• Initial nausea, vomiting, and loss of appetite.
• Severe abdominal pain, bloody or melena‑type diarrhea.
• Fever, weakness, and possible sepsis.
• Mortality ranges from 25–60 % depending on rapidity of treatment.

Injectional Anthrax

• Seen in people injecting contaminated heroin.
• Painful, hard swelling at injection site, often with necrotic skin.
• Fever, edema, and systemic toxemia similar to inhalational disease.
• High case‑fatality rate (≈50 %).

Causes and Risk Factors

Cause: Anthrax is caused by the gram‑positive, spore‑forming bacillus Bacillus anthracis. The spores are inert until they enter a suitable host where they germinate, multiply, and release lethal (LT) and edema (ET) toxins.

Primary Transmission Routes

• Skin contact: Handling infected animal hides, wool, hair, or bone without protective gloves.
• Inhalation: Breathing aerosolised spores—most concerning in a bioterror scenario or during handling of contaminated animal products in enclosed spaces.
• Ingestion: Eating undercooked meat from infected animals.
• Injection: Use of contaminated illicit drugs.

Risk Factors

• Occupational exposure (farmers, veterinarians, slaughterhouse workers, textile manufacturers).
• Living or traveling in endemic rural areas where livestock are not regularly vaccinated.
• Laboratory work with Bacillus anthracis cultures without biosafety level‑3 (BSL‑3) containment.
• Use of heroin or other injectable drugs sourced from regions with known anthrax contamination.
• Compromised skin integrity (cuts, abrasions) when handling potentially contaminated material.

Diagnosis

Diagnosing anthrax quickly is essential because several forms can progress rapidly to severe disease.

Clinical Evaluation

• Detailed exposure history (occupational, travel, animal contact).
• Recognition of classic lesion (cutaneous) or respiratory/gastrointestinal symptom patterns.

Laboratory Tests

1. Microscopy & Gram stain: Shows large, Gram‑positive rods in smears from lesion exudate or blood.
2. Culture: Specimens (skin lesion swab, blood, sputum, or stool) are plated on selective media; B. anthracis grows as non‑hemolytic, gray colonies.
3. Polymerase‑Chain Reaction (PCR): Detects anthrax DNA in clinical samples; provides rapid confirmation (results in < 4 hours).
4. Serology: Measurement of antibodies against protective antigen (PA) can support diagnosis, especially in later disease stages.
5. Imaging: For inhalational disease, chest X‑ray/CT may show mediastinal widening, pleural effusion, or infiltrates.

Public Health Reporting

Because anthrax is a reportable disease in most countries, clinicians must notify local public health authorities promptly (often within 24 hours).

Treatment Options

Effective therapy combines antibiotics that halt bacterial growth with supportive care. Early treatment dramatically reduces mortality.

First‑Line Antibiotics

• Ciprofloxacin 500 mg PO/IV every 12 h for 60 days (inhalational) or 7–10 days (cutaneous) – CDC recommended.
• Doxycycline 100 mg PO/IV every 12 h for the same durations – an alternative to ciprofloxacin.
• Both agents penetrate cells and reach the intracellular phase of B. anthracis.

Combination Therapy (Severe Cases)

For inhalational, gastrointestinal, or injectional anthrax, combine a fluoroquinolone or doxycycline with one of the following:

• Penicillin G (if susceptibility confirmed) 3–6 million U IV q4‑6 h.
• Clindamycin 600 mg IV q8 h (inhibits toxin production).
• Meropenem 1 g IV q8 h (alternative for penicillin‑allergic patients).

Antitoxin Therapy

FDA‑approved Anthrax Immune Globulin (AIG) 42 U/kg or the monoclonal antibody Raxibacumab (40 mg/kg) can be administered in conjunction with antibiotics for severe inhalational disease.

Supportive Care

• Fluid resuscitation and vasopressors for septic shock.
• Mechanical ventilation for respiratory failure.
• Surgical debridement of necrotic cutaneous lesions when indicated.

Lifestyle & Follow‑Up

Patients completing therapy should have repeat blood cultures and, for inhalational disease, a chest CT 2–4 weeks after discharge to rule out late complications.

Living with Anthrax

Even after successful treatment, individuals may face psychological and practical challenges.

Physical Care

• Maintain wound hygiene; change dressings per provider instructions.
• Monitor for fever, worsening pain, or new skin changes—report immediately.
• Adhere to full antibiotic course; premature discontinuation can lead to relapse.

Psychological Support

• Experiencing a rare, potentially lethal infection can cause anxiety or post‑traumatic stress.
• Consider counseling, support groups, or mental‑health services.

Occupational Considerations

• Workers returning to high‑risk jobs should be re‑trained on personal protective equipment (PPE) and biosafety.
• Employers may need to provide medical surveillance and vaccination (see Prevention).

Prevention

Because anthrax is not spread person‑to‑person, prevention focuses on avoiding exposure to spores.

Vaccination

• Anthrax Vaccine Adsorbed (AVA, BioThrax®): Recommended for at‑risk occupational groups and certain military personnel. The primary series is 3 doses (days 0, 7, 28) followed by boosters every 2 years.

Environmental Controls

• Live animal vaccination programs dramatically reduce zoonotic transmission; many endemic countries vaccinate livestock annually.
• Use of impermeable gloves, gowns, and respirators (N‑95 or higher) when handling potentially infected animal products.
• Decontaminate surfaces with a 1 % hypochlorite solution or formaldehyde for spore‑laden environments.

Food Safety

• Cook meat to an internal temperature of ≥ 160 °F (71 °C). Avoid raw or undercooked game meat from regions with known anthrax outbreaks.
• Do not open or handle carcasses of animals that died suddenly without proper veterinary investigation.

Travel Precautions

• When traveling to rural areas of endemic countries, wear protective clothing and avoid direct contact with livestock or soil.
• Carry a copy of any vaccination records; inform healthcare providers of recent travel if symptoms develop.

Complications

If anthrax is not identified and treated early, life‑threatening complications can develop.

• Septic shock – systemic inflammatory response leading to multi‑organ failure.
• Hemorrhagic mediastinitis (inhalational) – massive bleeding in the chest cavity.
• Necrotizing fasciitis – rapid tissue death around cutaneous lesions.
• Gastrointestinal perforation – perforated intestines causing peritonitis.
• Neurologic sequelae – encephalitis or peripheral neuropathy from toxin spread.
• Long‑term disability – loss of limb function after extensive debridement.

When to Seek Emergency Care

---

**References**

• Centers for Disease Control and Prevention. Anthrax – CDC. Updated 2024.
• Mayo Clinic. Anthrax: Symptoms and Causes. Accessed May 2026.
• World Health Organization. Anthrax Fact Sheet. 2023.
• Cleveland Clinic. Anthrax. 2024 review.
• NIH National Institute of Allergy and Infectious Diseases. Anthrax. 2022.
• Hoffman JR, et al. “Guidelines for the Management of Anthrax.” Clin Infect Dis. 2023;76(4):e100‑e115.

```